Taking a New Look At Contraceptives

The article by N.W. Pirie (The Scientist, January 26, 1987, p. 19) calls for a renewed search for novel methods of birth control. Pirie is right in highlighting this as a neglected area worth more attention than it currently receives. Spermicides are a logical choice to interrupt fertility, and the only major drawback of current products is a moderate failure rate. Pirie rightly points to the need to aggressively apply insights into sperm function to contraceptive development. As Pine suggests,

Written byRobin Foldesy
| 2 min read

Register for free to listen to this article
Listen with Speechify
0:00
2:00
Share

As Pine suggests, interfering with hyaluronidase, the sperm enzyme that allows penetration of the outer ovum vestments, may be particularly appropriate. From his research in the 1940s, the concept of preventing sperm penetration of the ovum by enzyme inhibition has emerged. Considerable work has since been done. A good review is L.J.D. Zaneveld's article in Research Frontiers in Fertility Regulation, vol. 2, no. 3, pp. 1-14, 1982.

Present vaginal contraceptives use non-ionic surfactant compounds such as nonoxynol-9 as their active ingredient. No new active ingredients have been introduced for some years now, but several, such as Dpropranolol, are under development. The recent surge in litigation involving vaginal spermicides may force the manufacturers to remove nonoxynol-9 from the marketplace purely for economic reasons. This would be particularly troublesome not only because new compounds are several years away from the marketplace, but because contraceptives using nonoxynol-9 have been shown to reduce significantly ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies